Atrogi Tests ATR-258 Pill for Fat Loss and Muscle Growth
A new experimental pill called ATR-258 reduces body fat while simultaneously increasing muscle mass in early human testing. Developed by the biotechnology company Atrogi, the drug targets skeletal muscle through a biased signaling mechanism that activates pathways responsible for muscle growth. Researchers tested the treatment on 13 overweight or obese men during an eight-week clinical trial at the University of Copenhagen, where participants received a once-daily dose.
During the eight-week trial, participants lost an average of 1.1 kilograms of fat and gained 0.8 kilograms of lean mass. The trial participants also improved their leg strength by 13 percent. These early results emerge as the popularity of GLP-1 medications continues to grow, treatments that frequently lead to reductions in both fat and muscle mass. Atrogi’s experimental compound aims to offer a different therapeutic profile by sparing muscle tissue while reducing weight.
University of Copenhagen Trial Results and Researcher Reactions
The magnitude of the physical improvements surprised the principal investigator at the University of Copenhagen, Morten Hostrup. Despite his extensive research experience with the specific molecular pathways targeted by the drug, Hostrup noted that he had not anticipated such substantial gains in lower-body power.
What struck me most was the magnitude of the signal in lower-extremity power,
Hostrup said. I know they can enhance power, but not to the extent we observed here. These findings give us a genuinely intriguing signal about the role of biased signalling in muscle physiology, and a strong rationale for taking ATR-258 forward into larger clinical trials.
Tore Bengtsson, Chief Scientific Officer and founder of Atrogi, emphasized the trial data. These first clinical data give us important confidence that our approach is translating,
Bengtsson said. To see fat loss alongside an increase in lean muscle mass and improvement in muscle function represents a truly differentiated profile, and is highly encouraging.
Atrogi plans to begin the next phase of clinical testing in 2027. Researchers aim to demonstrate a definitive proof of concept by testing ATR-258 in a larger group of participants. Beyond standard weight management and muscle-sparing weight loss, company leadership believes the drug’s signaling mechanism warrants investigation for therapeutic applications in sarcopenia and rare diseases characterized by substantial muscle loss and severe weakness.
Despite the promising early data, medical experts emphasize that ATR-258 remains strictly experimental. The medication is not intended to serve as an alternative to resistance training for otherwise healthy individuals.
Frequently Asked Questions About ATR-258
How does ATR-258 work in the body?
ATR-258 is designed to target skeletal muscle through a biased signaling mechanism. This mechanism activates specific biological pathways involved in muscle growth while simultaneously reducing body fat.
Who was included in the initial clinical trial?
The initial clinical trial at the University of Copenhagen evaluated ATR-258 in 13 overweight or obese men. Participants took the pill once a day for a total duration of eight weeks.
What specific physical improvements were recorded?
Over the eight-week study period, participants lost an average of 1.1 kilograms of fat and gained 0.8 kilograms of lean mass. The participants also improved their measured leg strength by 13 percent.